Older adults who have heart disease and also have weak muscles are much more likely to die within a year and a half. In this study, they had over five times the risk of dying compared to those with stronger muscles, even after accounting for other health factors.
See the scientific wording
Probable sarcopenia, defined by the EWGSOP II criteria as low muscle strength, is associated with a markedly elevated all-cause mortality risk in older adults with cardiovascular disease, with an adjusted hazard ratio of 5.46 (95% CI: 1.85-16.13) over an 18-month follow-up period.
Indication only — weak evidence
ObservationalOne low-scoring study points this way, but the evidence is still early.
What the research says
1 study reviewedSupporting (1)
Cohort StudyHuman2025
In this longitudinal cohort study of 439 older adults with cardiovascular disease, those classified as having probable sarcopenia (low grip strength) according to EWGSOP II criteria exhibited a significantly higher risk of mortality over 18 months, as reflected by an adjusted hazard ratio of 5.46.
Contradicting (0)
No contradicting studies found yet
That doesn't mean it's settled — it just means no study has tested the opposite.
Quality-weighted scoring: we follow the GRADE framework — each study is rated High, Moderate, Low, or Very Low based on study design, methodology rigor, and risk of bias. A single high-quality RCT can outweigh several weaker observational studies.
Scores reflect study quality, not just count.
In older adults with heart disease, having weak muscles is linked to a higher risk of dying. Weak muscles lead to less movement, which causes the body to handle sugar poorly and produce more inflammation. This inflammation damages blood vessels and makes heart disease worse, raising the chance of death.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting study
How Fit Body Science checks a claim
- 1
We isolate the claim
Health advice from videos, articles and studies is broken down into single, testable claims.
- 2
We find the research
Each claim is matched against peer-reviewed studies, with every source cited by DOI.
- 3
We grade the evidence
Studies are scored on methodology, statistical rigor, transparency and publication quality.
The fitness and health internet is full of confident claims. We check them against real research.
Every claim on this site is traced back to peer-reviewed studies, scored on methodology and reporting quality, and given a verdict you can audit yourself — sources, DOIs and all.
- Full evidence breakdown and mechanism chains
- Ask our AI anything about a claim or its studies
- Get notified when new research changes a verdict
Older adults who have heart disease and also have weak muscles are much more likely to die within a year and a half. In this study, they had over five times the risk of dying compared to those with stronger muscles, even after accounting for other health factors.
Mechanism
1 studyWeak muscles in older heart patients lead to less activity and more inflammation, which damages blood vessels and makes heart problems worse. This increases the chance of dying.
In older adults with heart disease, having weak muscles is linked to a higher risk of dying. Weak muscles lead to less movement, which causes the body to handle sugar poorly and produce more inflammation. This inflammation damages blood vessels and makes heart disease worse, raising the chance of death.
Low muscle strength in older adults with cardiovascular disease reflects reduced muscle mass and impaired neuromuscular function, leading to decreased physical activity and mobility.
Reduced physical activity results in decreased glucose uptake by muscles and increased systemic inflammation, characterized by elevated pro-inflammatory cytokines such as IL-6 and TNF-alpha.
Chronic inflammation and insulin resistance contribute to endothelial dysfunction, increased oxidative stress, and progression of atherosclerosis.
These pathological alterations exacerbate existing cardiovascular disease, leading to increased risk of fatal cardiovascular events and all-cause mortality.
Evidence from Studies
Supporting (1)
Community contributions welcome
Contradicting (0)
Community contributions welcome
Score Breakdown
No multi-axis breakdown available yet. The overall Pro / Against score above is the best signal.
- No clinical evidence is available; the score reflects mechanistic plausibility only.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Systematic Review and Meta-Analysis of Cohort Studies on Sarcopenia and Mortality in Older Adults with Cardiovascular Disease
A systematic search of MEDLINE, Embase, and Cochrane databases for observational studies (cohort and case-control) reporting mortality outcomes in older adults with CVD and sarcopenia, followed by meta-analysis of adjusted hazard ratios with assessment of heterogeneity and publication bias.
Randomized Controlled Trial of Resistance Training vs. Usual Care on Mortality in Older Adults with CVD and Probable Sarcopenia
A multicenter, parallel-group RCT enrolling older adults (≥65 years) with CVD and probable sarcopenia (EWGSOP II criteria). Participants randomized to a structured resistance training program vs. usual care. Primary outcome is all-cause mortality over 18 months, with secondary outcomes including muscle strength and physical performance. Blinded outcome assessment.
Prospective Cohort Study of Older Adults with CVD Assessing Sarcopenia Status and 18-Month Mortality
A prospective cohort study enrolling a representative sample of older adults (≥65 years) with established CVD. At baseline, assess sarcopenia using EWGSOP II criteria (handgrip strength). Follow participants for 18 months to record all-cause mortality. Use Cox proportional hazards models to estimate adjusted hazard ratios, controlling for age, sex, comorbidities, frailty, and other relevant covariates.
Case-Control Study Comparing Prevalence of Sarcopenia in Deceased vs. Alive Older Adults with CVD
Select cases as older adults with CVD who died within 18 months of a baseline assessment, and controls as those who survived. Match on age, sex, and CVD severity. Ascertain sarcopenia status from medical records or baseline measures of muscle strength (if available). Calculate odds ratios for mortality associated with sarcopenia, adjusting for potential confounders.
Cross-Sectional Study Examining the Relationship Between Sarcopenia and Subclinical Mortality Risk Markers in CVD Patients
Assess sarcopenia (EWGSOP II) and measure biomarkers of mortality risk (e.g., CRP, IL-6, gait speed) in a representative sample of older adults with CVD. Use regression models to examine cross-sectional associations, adjusting for age, sex, and comorbidities.